Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 52,627 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 52,627 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $0.93, for a total value of $48,943.11. Following the transaction, the insider owned 5,428,912 shares in the company, valued at approximately $5,048,888.16. This trade represents a 0.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $62,344.56.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $57,312.60.
• On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $65,886.92.

Werewolf Therapeutics Price Performance

Shares of HOWL stock traded down $0.07 during trading on Thursday, hitting $0.85. The company had a trading volume of 465,207 shares, compared to its average volume of 732,451. The firm has a market capitalization of $41.49 million, a P/E ratio of -0.53 and a beta of 0.72. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock’s 50-day moving average price is $1.55 and its 200 day moving average price is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the second quarter worth $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $48,000. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at $71,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth $92,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Bank of America dropped their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. JMP Securities reduced their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.